Exhibits several functions, including D2 dopamine receptor binding activity; enzyme binding activity; and protein domain specific binding activity. Involved in several processes, including positive regulation of transport; regulation of plasma membrane bounded cell projection organization; and regulation of signal transduction. Localizes to several cellular components, including the Golgi apparatus; cytoplasmic vesicle; and postsynaptic density, intracellular component. Colocalizes with the growth cone. Human ortholog(s) of this gene implicated in Charcot-Marie-Tooth disease dominant intermediate B; centronuclear myopathy 1; and lethal congenital contracture syndrome. Orthologous to human DNM2 (dynamin 2); PARTICIPATES IN platelet-derived growth factor signaling pathway; syndecan signaling pathway; vascular endothelial growth factor signaling pathway; INTERACTS WITH 2,2',5,5'-tetrachlorobiphenyl; 2,4-dinitrotoluene; 2,6-dinitrotoluene.
[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of DNM2 mRNA, Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to DNM2 gene]
[Arsenic Trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of DNM2 mRNA
[Arsenic Trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of DNM2 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNM2 mRNA
[Maneb co-treated with Paraquat] results in decreased expression of DNM2 mRNA, Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of DNM2 mRNA]
[arsenic trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of DNM2 mRNA
[Maneb co-treated with Paraquat] results in decreased expression of DNM2 mRNA, Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of DNM2 mRNA]
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNM2 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNM2 mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
posesses an amino-terminal GTPase domain, a central coiled-coil assembly domain, a pleckstrin homology domain, a carboxy terminal coiled -coil region (assembly or GTPase effector domain), a baic proline-rich domain
controls vesicular budding events like synaptic vesicle recycling, receptor-mediated endocytosis, caveolae internalization, phagocytosis and secretory vesicle budding from trans-Golgi network; may be involved in membrane scission
Gene-Chemical Interaction Annotations
